<DOC>
<DOCNO>EP-0614663</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Pharmaceutical composition containing a general anaesthetic and selegiline
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3138	A61K3138	A61P2300	A61K31135	A61P2300	A61P3902	A61K31135	A61P3900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61K	A61P	A61P	A61K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P23	A61K31	A61P23	A61P39	A61K31	A61P39	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to a veterinary anaesthetic pharmaceutical composition containing a general anaesthetic chosen from phencyclidine derivatives such as ketamine or tiletamine, as well as 0.015 to 1.25 molar equivalent(s) of selegiline, combined in a single pharmaceutical dosage form or presented separately.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SANOFI ELF
</APPLICANT-NAME>
<APPLICANT-NAME>
SANOFI SANTE NUTRITION ANIMALE
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BOIVIN ELIANE
</INVENTOR-NAME>
<INVENTOR-NAME>
OVAERT PATRICIA
</INVENTOR-NAME>
<INVENTOR-NAME>
BOIVIN, ELIANE
</INVENTOR-NAME>
<INVENTOR-NAME>
OVAERT, PATRICIA
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Veterinary Pharmaceutical compositions for inducing
general anaesthesia, characterised in that it comprises,

together with conventional carriers, a general
anaesthetic of the phencyclidine type such as ketamine

or tiletamine or one of the pharmaceutically acceptable
salts thereof as well as 0.015 to 1.25 molar equivalents

of selegiline or one of the pharmaceutically acceptable
salts thereof, combined in a single pharmaceutical

preparation or presented separately.
Composition according to claim 1, characterised in
that it comprises the compound of the phencyclidine type

or one Of the salts thereof, as well as 0.050 to 1.0
molar equivalents of selegiline or one of the

pharmaceutically acceptable salts thereof.
Composition according to claim 1, characterised in
that it comprises ketamine or one of the salts thereof

and 0.25 to 1.0 molar equivalents, based on the
ketamine, of selegiline or one of the salts thereof.
Composition according to one of claims 1 to 3,
characterised in that a single dose contains the

quantity needed to administer from 1 to 4 mg/kg of
selegiline HCl to a dog or cat.
Use of selegiline or one of the pharmaceutically
acceptable salts thereof for the production of a

veterinary medicament which prevents the side effects of
anaesthesia with ketamine or tiletamine or with the

pharmaceutically acceptable salts thereof, notably
muscular hypertonia, epileptiform seizures and recurrent

hallucinations.
</CLAIMS>
</TEXT>
</DOC>
